ACVRL1 (activin receptor like-protein 1) mediates tumor angiogenesis; however, its utility as a predictive or prognostic biomarker in colorectal cancer is unclear. We present the first evidence from a phase III study that intratumoral ACVRL1 expression is associated with tumor response and survival among metastatic colorectal cancer patients undergoing first-line bevacizumab chemotherapy. These results could guide the selection of colorectal cancer patients for chemotherapy and antiangiogenic therapy. Background: No biomarkers exist to predict benefit from antiangiogenic therapy in metastatic colorectal cancer patients. ACVRL1 (activin receptor like-protein 1) encodes for ALK1, a member of the transforming growth factor-b receptor family, which directs pathologic angiogenesis. We examined the intratumoral expression of ACVRL1 and other angiogenesis pathway-related genes to identify molecular markers in the TRIBE study. Materials and Methods: Of 503 randomized patients, 228 had sufficient tissue for analysis. Formalin-fixed paraffin-embedded specimens were examined for expression of VEGF-A, VEGF-B, VEGF-C, VEGFR1, VEGFR2, ACVRL1, EphB4, and EGFL7 using reverse transcription polymerase chain reaction. A maximal c 2 approach was used to determine the messenger RNA levels associated with progression-free survival (PFS), overall survival (OS), response rate, early tumor shrinkage, and depth of response. Recursive partitioning trees were constructed to identify composite prognostic biomarker profiles. External validation was conducted in silico using the Oncomine database. Results: High ACVRL1 expression was associated with superior OS in both treatment arms (FOLFOXIRI [5-fluorouracil, leucovorin, oxaliplatin, irinotecan]-bevacizumab, 32.7 vs. 13.5 months, hazard ratio [HR], 0.38, P ¼ .023; FOLFIRI [5-fluorouracil, leucovorin, irinotecan]-bevacizumab, 35.1 vs. 22.0 months, HR, 0.36, P ¼ .006) and prolonged PFS (11.7 vs. 5.9 months, multivariate HR, 0.17; P ¼ .001) for patients receiving FOLFOXIRI-bevacizumab on univariate and multivariate analyses. In recursive partitioning analysis, ACVRL1 was the strongest discriminator of the response rate, PFS, and OS in patients receiving FOLFOXIRI-bevacizumab and of OS in patients receiving FOLFIRI-bevacizumab. In silico validation Clinical Colorectal Cancer September 2018 -e471 revealed significant associations between ACVRL1 expression, disease recurrence, and 1-year survival (P < .05) among all colorectal cancer stages. Conclusion: ACVRL1 expression could serve as a prognostic biomarker in metastatic colorectal cancer patients receiving chemotherapy and bevacizumab and warrants further evaluation in prospective studies.
Introduction
Fluoropyrimidine-based regimens combining either oxaliplatin or irinotecan with bevacizumab 1, 2 have been mainstays of metastatic colorectal cancer (mCRC) treatment. Recent efforts to improve on the standard of care have introduced triple-drug chemotherapy regimens (FOLFOXIRI [5-fluorouracil, leucovorin, oxaliplatin, irinotecan]) and bevacizumab as an option for first-line mCRC management. 3 The triplet plus bevacizumab (TRIBE) study 3 4 Despite these advancements, no biomarkers have been established to select patients most likely to benefit from bevacizumabbased chemotherapy regimens. Also, correlative studies have thus far yielded conflicting results regarding the clinical utility of angiogenesis biomarkers in CRC. Gene expression of vascular endothelial growth factor (VEGF) ligands and receptors has been associated with clinicopathologic staging and prognosis 5, 6 ; however, other retrospective analyses 7, 8 and randomized studies [9] [10] [11] have been largely nonconfirmatory. Owing to the complexity of tumor vascularity and presence of VEGF-independent angiogenic and drug-resistance mechanisms, 12 other genes have been explored as candidate biomarkers of bevacizumab efficacy. Activin receptor likeprotein 1 (ACVRL1), 13, 14 epidermal growth factor-like domain 7 (EGFL7), 15, 16 and EphrinB4 (EphB4) 17, 18 have been implicated in malignant angiogenesis, although data regarding their use as biomarkers are sparse and varied. Differences in patient populations, treatment rendered, and measures of gene expression are confounding factors that have precluded definitive conclusions about these biomarkers. Evidence from randomized trials should provide a strong rationale for their clinical use and might offer useful hypotheses regarding the molecular interactions affecting drug sensitivity and patient outcomes. Accordingly, we sought to determine the prognostic value of molecular markers reflecting angiogenesis (VEGF-A, VEGF-B, VEGF-C, VEGFR1, VEGFR2, ACVRL1, EphB4, and EGFL7) among mCRC patients receiving first-line chemotherapy and bevacizumab in the TRIBE study. We examined the associations between the messenger RNA (mRNA) expression of individual genes and outcomes and then constructed recursive partitioning trees to identify clinically meaningful gene expression signatures.
Materials and Methods

Study Design and Patient Population
The TRIBE study accrued 508 patients across 34 Italian centers with unresectable mCRC who had not received chemotherapy or biologic therapy for their metastatic disease but could have received previous adjuvant chemotherapy. 3 Patients were randomized to receive FOLFOXIRI-bevacizumab (experimental group) or FOLFIRI-bevacizumab (control group) at 2-week intervals for 12 cycles, followed by 5-fluorouracil and bevacizumab maintenance therapy until disease progression. The study design, eligibility criteria, treatment details, follow-up data, and clinical outcomes have been previously reported. The respective local ethics committees approved the protocols, which were conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent for blood and tissue specimen collection for translational studies. Archived formalin-fixed paraffin-embedded (FFPE) tumor tissue was obtained from either the primary tumor or metastasis before randomization. Patients with sufficient tissue for examination of ! 1 molecular marker were included in the present study. The present retrospective correlative analysis conformed to the reporting guidelines established by the REMARK (reporting recommendations for tumour marker prognostic studies) criteria. 19 
Tumor Tissue Preparation and Gene Expression Analysis
Hematoxylin and eosin-stained sections of all FFPE tissues were evaluated by a board-certified pathologist (G.Z.) for tumor content. The FFPE specimens were dissected, and 10-mm-thick slides were obtained from areas with the greatest tumor concentration and mounted on uncoated glass slides. For histologic diagnosis, 3 sections representative of the beginning, middle, and end of the tissue were stained with hematoxylin and eosin using the standard method. Before microdissection, the sections were deparaffinized in xylene for 10 minutes, hydrated with 100%, 95%, and 70% ethanol, and then washed in water for 30 seconds. After microdissection of the tumor cells, the sections were stained with nuclear fast red (American Master Tech Scientific, Inc, Lodi, CA) for 20 seconds and rinsed in water for 30 seconds. The samples were then dehydrated with 70%, 95%, and 100% ethanol for 30 seconds each, followed by xylene for 10 minutes. The slides were then completely air-dried. Laser capture microdissection (P.A.L.M. Microlaser Technologies AG, Bernried, Germany) was performed in all tumor samples to ensure that only tumor cells were dissected. 20 The dissected particles of tissue were transferred to a reaction tube containing 400 mL of RNA buffer for lysis of the tumor cells.
After lysis of the tumor cells, RNA and DNA were isolated separately from the specimen. RNA isolation from paraffin-embedded e472 -Clinical Colorectal Cancer September 2018 ACVRL1 Expression in mCRC samples was performed using a proprietary procedure defined by Response Genetics, Inc. (RGI; US Patent no. 6248535). The RNA was then reverse-transcribed to complementary DNA (cDNA), as described previously. 21 DNA was either directly extracted or back extracted from the organic phase, both using an RGI-patented method (US Patent no. 6248535). Quantitation of gene mRNA expression levels of VEGF-A, VEGF-B, VEGF-C, VEGFR1, VEGFR2, ACVRL1, EphB4, EGFL7, and an internal reference (b-actin) cDNA was performed using a fluorescence-based real-time detection method (ABI PRISM 7900 TaqMan Sequence Detection System; PerkinElmer Applied Biosystems, Waltham, MA), as previously described. 22 Isolated RNA was reverse-transcribed to cDNA, followed by reverse transcription polymerase chain reaction (RT-PCR) using specific primers and probes. The PCR reaction mixture consisted of 1200 nmol/L of each primer; a 200-nmol/L probe; 0. KRAS mutation analysis was performed using RGI-designed mutation assay by RT-PCR with specifically designed primers and probes to detect each of the following mutations: Gly12Ala (GGT>GCT) 522, Gly12Asp (GGT>GAT) 521, Gly12Arg (GGT>CGT) 518, Gly12Cys (GGT>TGT) 516, Gly12Ser (GGT>AGT) 517, Gly12Val (GGT>GTT) 520, and Gly13Asp (GGC>GAC) 532. After RT-PCR, all collected data were analyzed using an RGI Excel template, and using the D Ct values, the mutation status was established. BRAF V600E mutations were detected using dye terminator sequencing.
Statistical Analysis
The mRNA expression levels of VEGF-A, VEGF-B, VEGF-C, VEGFR1, VEGFR2, ACVRL1, EphB4, and EGFL7 were summarized and analyzed using Wilcoxon 2-sample tests or Kruskal-Wallis tests to detect differences according to gender, primary tumor site (left vs. right), and KRAS and BRAF mutation status.
The maximal c 2 approach was used to identify which mRNA levels might delineate subsets of patients more likely to benefit from FOLFIRI-bevacizumab in terms of PFS. From these analyses, the following optimal cutoff points were determined (expression level A classification and regression tree method, using recursive partitioning, was used to explore gene expression variables to identify homogenous subgroups for tumor response, PFS, and OS. 23 Recursive partitioning analysis is a nonparametric statistical method for modeling a response variable and multiple predictors. Recursive partitioning analysis includes 2 essential processes: tree growing and tree pruning. The splitting rule of recursive partitioning is based on the Gini diversity index (1 minus the sum of the squared probabilities over all levels of response) or deviance, whenever appropriate. Our recursive partitioning analysis included all patients with tumor tissue specimens who were evaluable for tumor response (n ¼ 228).
Genes that showed significant associations with outcomes in both treatment groups were then evaluated in the Oncomine microarray data compendium, as an external validation. Differential expression of ACVRL1 in relevant studies was compiled and annotated for significance using the statistical measures provided by the Oncomine platform (Thermo Fisher Scientific, Ann Arbor, MI).
All values are reported as the medians and range or cutoff values, with P .05 the cutoff for statistical significance. P values for the associations between gene expression levels and each clinical outcome were adjusted for multiple testing using the permutationbased false discovery rate with confidence intervals (CIs). 24 Analyses were performed using Statistical Analysis Software, version 9.4 (SAS Institute Inc, Cary, NC) and functions rpart and fdrci of the R package (R Foundation for Statistical Computing, Vienna, Austria; available at: https://www.R-project.org/).
Results
Patient Characteristics and Baseline Intratumoral Gene Expression
Of the 508 patients enrolled in the TRIBE study, 228 (45%) had tumor tissue sufficient for gene expression analysis (Supplemental Figure 1 ; available in the online version). The patient and tumor characteristics were similar between the FOLFOXIRI-bevacizumab and FOLFIRI-bevacizumab subgroups in the present study and to the overall trial population ( Table 1 ). The median follow-up period for patients in the present correlative analysis was 49.9 months. Patients receiving FOLFOXIRI-bevacizumab had a superior RR (68.5% vs. 58.8%) and longer PFS (median PFS, 11.7 vs. 10.8 months), with a similar OS (median OS, 32.7 vs. 33.0 months; Table 1 ).
Baseline tumor mRNA expression was determined using RT-PCR for the following genes: VEGF-A, VEGF-B, VEGF-C, VEGFR1, VEGFR2, ACVRL1, EphB4, and EGFL7. Expression of these genes did not differ significantly between patients in the experimental and control groups (Supplemental Table 2 ; available in the online version). In subgroup analysis, men had significantly greater VEGF-B expression compared with women (P ¼ .02). Patients with KRAS wild-type tumors had increased EphB4 expression relative to those with KRAS mutant tumors (P ¼ .04), and patients whose tumors harbored V600E BRAF mutations had significantly increased ACVRL1 expression compared with patients with BRAF wild-type tumors (P ¼ .03). When RAS and BRAF mutation status were both considered, RAS/BRAF wild-type tumors had significantly greater VEGF-A (P ¼ .026) and VEGF-B (P ¼ .028) expression relative to those with either RAS or BRAF mutations (Supplemental Table 3 ; available in the online version). There were no significant differences in baseline gene expression based on primary tumor location (Supplemental Table 4 ; available in the online version). (40) 49 (43) 102 (41) 44 (39) Primary tumor site .59
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Wild-type 99 (39) 51 (44) 94 (38) 48 (42) Mutant 95 (38) 60 (52) 103 (41) 64 ( (18) 24 (21) 48 (19) 25 (22) RAS mutant 118 (47) 73 (63) 116 (46) 72 (64) BRAF mutant 12 (5) 8 (7) 16 (6) 11 (10) Unknown 78 (31) 10 (9) 70 (28) 5 (4) Adjuvant chemotherapy a 32 (13) 20 (17) 32 (13) 13 (12 Increased VEGF-C expression was associated with a lack of benefit from FOLFIRI-bevacizumab for PFS (8.6 vs. 11.3 months; HR, 2.19; 95% CI, 1.10-4.37; P ¼ .026) on multivariate analysis but not for OS. VEGF-C was not associated with PFS or OS in patients receiving FOLFOXIRI-bevacizumab.
VEGFR1 expression had opposing prognostic associations in both treatment groups. In patients randomized to FOLFIRIbevacizumab, high VEGFR1 expression was associated with inferior PFS (9.3 vs. 20.0 months; HR, 4.89; 95% CI, 1.24-19.27; P ¼ .023). In contrast, in patients receiving FOLFOXIRI-bevacizumab, increased VEGFR1 expression was associated with a trend toward improved PFS (11.3 vs. 8.9 months; HR, 0.23; 95% CI, 0.05-1.20; P ¼ .082), with a similar trend for OS (33.6 vs. 18.8 months; HR, 0.51; 95% CI, 0.19-1.36; P ¼ .18).
On univariate analysis, increased EGFL7 expression was associated with inferior OS in patients receiving FOLFIRI-bevacizumab (26.3 vs. 33.5 months; HR, 1.82; 95% CI, 1.07-3.11; P ¼ .020). However, this effect was not seen on multivariable analysis or in patients treated with FOLFOXIRI-bevacizumab.
Finally, increased VEGFR2 expression was associated with shortened PFS (9.3 vs. 11.6 months; HR, 1.97; 95% CI, 1.03-3.77; P ¼ .041) and OS (32.1 vs. 33.5 months; HR, 1.88; 95% CI, 1.02-3.46; P ¼ .042) in patients treated with FOLFIRIbevacizumab. This trend was not evident in the FOLFOXIRIbevacizumab group.
Associations Between Gene Expression and Overall RR, Early Tumor Shrinkage, and Depth of Response
Among patients receiving FOLFIRI-bevacizumab, decreased EphB4 (71% vs. 23%; P ¼ .001) and VEGFR2 (77% vs. 41%; P ¼ .002) expression was each associated with a significantly greater RR compared with those with low expression of either marker. No significant relationships were found between the other genes and the RR in either treatment group (Supplemental Table 5 ; available in the online version).
Spearman correlations were then determined between the gene expression levels and early tumor shrinkage (ETS) and the depth of response (DoR). ETS was defined as the percentage of tumor shrinkage at 8 weeks compared with baseline, and DoR was defined as the percentage of tumor shrinkage at the nadir, in the absence of new lesions or progression of nontarget lesions.
We have previously shown that patients enrolled in the TRIBE study with an ETS of ! 20% achieved a superior PFS and OS. 25 Within the FOLFOXIRI-bevacizumab group, low VEGF-A expression was associated with ETS (P ¼ .017). In the FOLFIRIbevacizumab group, lower EphB4 expression (r 2 ¼ À0.28; P ¼ .0082) or low VEGF-C expression (r 2 ¼ À0.22; P ¼ .034) demonstrated modest correlations with DoR. Finally, using 20% as a cutoff to dichotomize ETS, low VEGFR2 (P ¼ .023) and EphB4 (P ¼ .049) expression were both significantly associated with ETS among patients treated with FOLFIRI-bevacizumab (Supplemental Figure 2 ; available in the online version).
Recursive Partitioning Analysis of Candidate Molecular Markers
ACVRL1 expression was the strongest positive discriminant of OS in both treatment groups, and VEGF-A was also a common discerning biomarker between the treatment arms (Supplemental Figure 3 ; available in the online version). With respect to PFS, VEGF-C expression was the main determinant among patients receiving FOLFIRI-bevacizumab. In contrast, ACVRL1 was more prognostic in the FOLFOXIRI-bevacizumab group (Supplemental Figure 4 ; available in the online version). Among the candidate markers, EphB4 expression provided the best separation between responders and nonresponders in the FOLFIRI-bevacizumab group, with low EphB4 expression associated with an increased tumor response (Supplemental Figure 5 ; available in the online version). In the FOLFOXIRI-bevacizumab group, ACVRL1 was the primary discriminant of the RR. VEGF-B expression was associated with the RR in both treatment groups.
External In Silico Validation of ACVRL1 Expression
We queried the Oncomine microarray compendium with progressively broad search filters. We found 4 relevant studies that had tested intratumoral ACVRL1 expression in patients with CRC: TCGA Colorectal, 26 Smith Colorectal, 27 Freeman Colorectal 2, 28 and Jorissen Colorectal 3. 29 The TCGA data set only included 19 patients with mCRC with a documented follow-up time. In addition, ACVRL1 expression was determined using a different platform (Illumina) compared with the other 3 studies (which used the Human Genome U133 Plus 2.0 Array). Therefore, that data set was not used for further analysis. Across the remaining 3 studies, which had included patients with all stages of CRC, increased ACVRL1 expression was significantly associated with improved recurrence-free survival and OS ( 
Discussion
To date, no biomarkers are available to select mCRC patients likely to benefit from antiangiogenic-based chemotherapy regimens. We examined the baseline intratumoral mRNA expression of genes involved in angiogenesis pathways to identify molecular surrogates of clinical outcomes. To the best of our knowledge, our correlative analysis of the TRIBE study is the first to reveal a potential prognostic role for ACVRL1 expression in mCRC patients receiving cytotoxic chemotherapy with bevacizumab.
Insights into the development and regulation of tumor vasculature have revealed VEGF-independent signaling pathways that partly mediate bevacizumab resistance. 12 One such pathway involves ALK1
(encoded by the ACVRL1 gene), a member of the transforming growth factor-b (TGF-b) receptor family, which directs physiologic and pathologic angiogenesis. 30 Along with TGF-b, ALK1 binds bone morphogenic protein 9 to phosphorylate Smads 1, 5, and 8 and activate transcription of proteins regulating vascular development and remodeling, 30, 31 along with cellular proliferation. 32 ALK1 also binds VEGFR3 to promote malignant lymphangiogenesis. 30, 33 Clinically, tumor ACVRL1 expression has been associated with survival in head and neck cancer patients 34 but has not been explored in CRC patients. In our analysis, high ACVRL1 expression was associated with both PFS and OS, lending evidence for its use as a prognostic marker in cancer patients treated with bevacizumab-based chemotherapy.
Another mechanism of VEGF-independent angiogenesis is mediated by EphB4, an aberrantly expressed receptor tyrosine kinase, 17, 35 with both tumor suppressor and oncogenic roles in CRC development. 36, 37 EphB4 and its solitary ligand, EphB2, 38,39 regulate vasculogenesis through bidirectional signaling, 40, 41 resulting in the activation of multiple downstream effectors 37 (eg, insulin-like growth factor, fibroblast growth factor, platelet-derived growth factor, epiregulin, amphiregulin) and pathways (eg, EGFR/Ras/MEK/ ERK, 36 Wnt-b-catenin, 38 PI3K/Akt/mTOR 41 ). In a retrospective study of mCRC patients receiving chemotherapy and bevacizumab, EphB4 expression was inversely associated with tumor response and survival. 18 Similarly, our data showed low EphB4 expression was associated with superior PFS in both treatment groups and with tumor response among patients receiving FOL-FIRI-bevacizumab. In our univariable and recursive partitioning analyses, we identified EGFL7 as a negative prognosticator for PFS and OS. This is in line with previous investigations associating EGFL7 overexpression with lymph node metastasis and inferior survival among colon cancer patients. 15 EGFL7 codes for an extracellular matrixassociated protein restricted to endothelial cells, whose expression is normally upregulated during angiogenesis and vascular injury. [42] [43] [44] [45] In vitro studies have revealed that EGFL7 blunts immunostimulatory cytokines (eg, interferon-g) and adhesion molecule production, allowing for escape from the antitumor immune response. 46, 47 In addition, EGFL7 has been shown to promote tumor angiogenesis in part by activating Notch signaling 46, 48 and VEGFR3 expression. 43, 46 In human cell lines, knockdown of EGFL7 suppresses endothelial cell proliferation and blood vessel formation. 43 In mice models, EGFL7 suppression has been found to enhance the efficacy of anti-VEGF therapeutic agents. 16 Altogether, our data further support EGFL7 as a prognostic marker and a potential therapeutic target.
Although the gene expression levels of different VEGF and VEGFR isoforms have been correlated with CRC tumor recurrence 49 and survival, 6 ,50,51 the evidence has been mixed, 7, 8 and such discrepancies can be attributed to heterogeneous gene expression within primary tumors 52 and between metastatic sites. 53, 54 In our study, low VEGF-C expression was associated with improved PFS in patients receiving FOLFIRI-bevacizumab. This is consistent with previous studies showing an inverse relationship between VEGF-C levels and survival in CRC patients. 52, 55 Mechanistically, cell line studies have revealed that VEGF-C, a ligand for the VEGFR2 and VEGFR3 receptors, promotes malignant angiogenesis and lymphangiogenesis, 56 as well as proliferation, invasion, and metastasis. 57 Our study also showed opposing relationships between VEGFR1 expression and survival in both treatment groups. The significance of these findings is unclear. Also, given the small number of patients with tissue sufficient for VEGFR1 analysis, these results should be interpreted with caution. VEGF-A, the therapeutic target of bevacizumab, did not emerge as a significant biomarker of tumor response or survival in either treatment group in our study. Although our recursive partitioning analysis identified VEGF-A as a potential marker for OS, the strength of this association was limited given the crossing of the corresponding Kaplan-Meier curves (data not shown). This is consistent with findings from the AVF2107 trial, which randomized patients to treatment with 5-fluorouracil and irinotecan with or without bevacizumab and also failed to demonstrate predictive or prognostic associations for VEGF-A expression. 9 In contrast, the VEGF-A splice variant, VEGF 165 b, might be a more appropriate marker for bevacizumab efficacy, as supported the results from a correlative analysis of the Eastern Cooperative Oncology Group 3200 trial.
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It is noteworthy that VEGF-C emerged as a marker of DoR and PFS, although it was not significantly associated with the Response Evaluation Criteria in Solid Tumors-defined overall RR. In line with the findings from the Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy (PRIME), 58 Cetuximab Combined With
Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL), 59 and Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (OPUS) 59 trials, a post hoc analysis of the TRIBE study 25 demonstrated significant associations between ETS and DoR and survival. The results from the present study provide a potential molecular surrogate to characterize such associations. Mindful of the limitations of subgroup analysis, these findings merit further investigation and suggest that refining efficacy outcomes to account for the onset and extent of response is necessary in patients receiving targeted therapies.
Certain limitations of our study should be acknowledged. Given the relatively small sample size of our retrospective analysis, larger biomarker-embedded prospective trials are required to validate our findings. In addition, the lack of a control group not receiving bevacizumab in the TRIBE study limited our ability to draw any conclusions about the predictive value of these biomarkers, which would be more clinically relevant. Similarly, the specificity of the 
Conclusion
The results of our study provide evidence for ACVRL1 as a potential biomarker in mCRC patients receiving first-line chemotherapy and bevacizumab. Because angiogenic mechanisms are complex, composite molecular profiles and not one particular marker will likely be necessary to adequately inform clinical decisions. Future translational investigations should delineate the interactions among the angiogenesis pathways that could affect the utility of these biomarkers.
Clinical Practice Points
Bevacizumab improves survival in mCRC patients treated with chemotherapy, yet not all patients benefit from antiangiogenic therapy. No validated biomarkers exist to predict for benefit from antiangiogenic-based chemotherapy regimens. ACVRL1 encodes for ALK1, a member of the TGF-b receptor family, which directs pathologic angiogenesis. We examined intratumoral expression of markers of angiogenesis (VEGF-A, VEGF-B, VEGF-C, VEGFR1, VEGFR2, ACVRL1, EphB4, and EGFL7) in mCRC patients enrolled in the TRIBE study. We found that high ACVRL1 expression was associated with superior OS in both treatment arms. In recursive partitioning analysis, ACVRL1 was the strongest discriminator of the RR, PFS, and OS in patients receiving FOLFOXIRI-bevacizumab and OS in patients receiving FOL-FIRI-bevacizumab. In silico validation revealed significant associations between ACVRL1 expression and disease recurrence and 1-year survival (P < .05) among all CRC stages. ACVRL1 expression might serve as a prognostic biomarker in mCRC patients receiving bevacizumab-based chemotherapy and warrants further evaluation in prospective studies. These results could guide the development of biomarkerembedded trials and the selection of CRC patients likely to benefit from antiangiogenic regimens. Forward Primer Reverse Primer Probe 
